A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Hartford, Christine M., Desai, Apurva A., Janisch, Linda, Karrison, Theodore, Rivera, Victor M., Berk, Lori, Loewy, John W., Kindler, Hedy, Stadler, Walter M., Knowles, Heather L., Bedrosian, Camille, Ratain, Mark J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147153/
https://ncbi.nlm.nih.gov/pubmed/19228743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2076
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk